Immunicum is open to discuss collaborations and license agreements with potential partners from the pharmaceutical/biotech industry and academic research groups. We are devoted to maximizing the commercial and therapeutic potential of our research in immuno-oncology, specifically in combination with therapeutics with complementary mechanisms of action, such as checkpoint inhibitors,kinase inhibitors and other immunotherapies. By combining our internal expertise and technologies with external research & development teams and forefront oncology innovations, we believe we can create powerful synergies to ultimately provide better treatment options for cancer patients.

Contact Us